Cargando…
Akt as a target for cancer therapy: more is not always better (lessons from studies in mice)
The PI3K/Akt signalling pathway is one of the most frequently altered signalling networks in human cancers and has become an attractive target in anticancer therapy. Several drugs targeting this pathway are currently in different phases of clinical trials. However, accumulating reports suggest that...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520506/ https://www.ncbi.nlm.nih.gov/pubmed/28557977 http://dx.doi.org/10.1038/bjc.2017.153 |